‘I was diagnosed with potentially deadly condition after taking weight-loss jab now offered on NHS'
A woman says she was diagnosed with potentially life-threatening pancreatitis less than two months after starting to take the weight-loss jab Mounjaro.
Julie Bishop, 55, decided to buy the drug online as part of a £120-a-month subscription after exhausting other avenues to lose weight.
Mounjaro, the brand name for tirzepatide, has become increasingly popular in the UK since it was licensed for sale, and this week became available on the NHS through a GP.
But despite losing two-and-a-half stone through taking the weekly jab for eight weeks, Ms Bishop had to stop after she was diagnosed with acute pancreatitis. The condition is when the small organ, located behind the stomach, becomes inflamed. It can lead to the pancreas becoming infected, leading to sepsis and organ failure that can be fatal.
'I suddenly got a severe pain around my stomach and when it became clear I couldn't walk it off, I went to the local walk-in centre,' the mental health worker told The Independent.
'When I got there, they did an ECG (electrocardiogram) and when I told them I took Mounjaro, they sent me by taxi to hospital where I was diagnosed with pancreatitis after a blood test.
'They said I had to stop taking Mounjaro as it could be linked. It was all very worrying for me, as the drug had been working really well.'
Following her diagnosis on 15 May, Ms Bishop suffered two more pancreatic 'attacks' which resulted in hospital visits, and she is now waiting to have a magnetic resonance imaging (MRI) to understand the extent of damage to her pancreas, and any complications.
Doctors cannot yet be sure the pancreatitis is linked to taking Mounjaro. One other possible cause could be high levels of cholesterol in the body, which can form gallstones through rapid weight loss and can block the pancreatic duct, leading to pancreatitis.
Her story comes as a new report highlights the possible danger linked to taking GLP-1 medicine weight loss and diabetes jabs, including Mounjaro.
Official figures from the Medicines and Healthcare products Regulatory Agency (MHRA) reveal that some 181 cases of acute and chronic pancreatitis were reported to be linked to Mounjaro since it was licensed, leading to the deaths of five people.
The figures come from voluntary medical reports of adverse incidents with medicines, and usage of a drug may have been coincidental to a condition rather than responsible for it.
However, Ms Bishop said more needed to be done to share the risks involved with taking the drugs.
She bought Mounjaro from an online retailer called Zava, which she said asked her to send basic photographs of her body and answer questions on her medical history before sending out the drugs.
She said she was concerned that the company, which is partnered with Asda in the UK, did not reply to her message alerting them to her diagnosis more than a month ago.
'I know a lot of people who take it, so I wasn't initially concerned over using it,' she said.
'I think it'd help if it was explained to people how important their organs, such as the pancreas, are to the body, and the damage a side effect can really cause.
'I'd be tempted to go back on it, but only through the NHS. I think these drugs should only really be coming to the public through NHS, potentially though paying for it, because of the risks involved.'
On Zava's website, the three steps for a weight loss consultation to get the jabs are a 'quick and simple' medical questionnaire, choosing a preferred treatment, and a doctor check.
Under 'rare' long-term side effects listed, it includes pancreatitis for Mounjaro.
From this week, people can also get the drug from a GP if they have a BMI of 40 or over, and one of four out of five conditions that include type 2 diabetes and high blood pressure. Ozempic and Wegovy weight-loss jabs are available on the NHS, but only after a referral to a specialist weight management service.
Earlier this month, the NHS's top doctor, Professor Sir Stephen Powis, said weight-loss jabs could become the most commonly used drugs, as an estimated 1.5 million people are now taking them in the UK.
He hailed the rollout of Mounjaro at GP surgeries as part of a fight against obesity, claiming that one day, they could become available in pharmacies.
But he also warned the drugs could be harmful if prescribed without the right checks and wraparound care.
'They can have side effects, including nausea, dehydration and inflammation of the pancreas, and a worrying number of people are continuing to access them without appropriate checks via the internet,' he said.
Zava's chief medical director Dr Zenon Andreou said he could not discuss Ms Bishop's case because of patient confidentiality. He said: 'We take the wellbeing of our patients very, very seriously and we pride ourselves in the way we treat them.
'We are aware that pancreatitis can be one of the side effects of weight-loss drugs. We will not prescribe the medication to anybody with pancreatitis. Regarding messages from patients and their journey with us, we respond to all messages that require medical attention to provide support from us.'
A spokesperson for Lilly, which produces Mounjaro, said a patient leaflet warned that an inflamed pancreas was an uncommon side effect, impacting up to 1 in 100 people. They added: 'We encourage patients to consult their doctor or other healthcare professional regarding any side effects they may be experiencing and to ensure that they are getting genuine Lilly medicine.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Fat jabs taken by millions linked to 560 cases of deadly side effect and 10 deaths
The Medicines and Healthcare products Regulatory Agency (MHRA) has revealed that more than 560 suspected cases of pancreatitis have been linked to GLP-1 drugs. Pancreatitis is inflammation of the pancreas, which can be either acute (sudden and short-term) or chronic (long-term and ongoing). GLP-1 drugs, or glucagon-like peptide-1 receptor agonists, are a class of medications primarily used to treat type 2 diabetes and, increasingly, obesity, such as Mounjaro, Wegovy, and Ozempic. Read more: State pension £11,973 warning to anyone turning 65 soon The UK's medicines regulator has said that since the drugs were approved, 181 cases of pancreatitis have been linked to tirzepatide, the active ingredient in Mounjaro. This includes five deaths. Additionally, 13 cases have been linked to semaglutide, found in Wegovy and Ozempic. One death has been linked here. While another jab, Liraglutide, has been tied to 116 suspected cases and one death. Exenatide has been linked to 101 cases, with three deaths. Dulaglutide and Lixisenatide, on the other hand, have been linked with 63 cases. No known deaths have been associated. Dr Alison Cave, MHRA's chief safety officer, said: "Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. "Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions - enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. "To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. "Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety." Pancreatitis can also be triggered by gallstones or alcohol. Yet, the MHRA believes there could be a genetic link in some patients, with the regulator launching a new study to investigate its findings further.
Medscape
an hour ago
- Medscape
Promising Weight-Loss Compound Targets Energy Expenditure
A new weight-loss compound targeting energy expenditure rather than appetite suppression showed early efficacy in a first-in-human study. The compound, SANA (MVD1; Eolo Pharma), activates creatine-dependent thermogenesis, a novel approach to obesity and metabolic disease compared to appetite suppression, explained Eolo Pharma CEO María Pía Garat. 'To our knowledge, SANA is the only small molecule in clinical development that targets this mechanism, and we expect growing interest in this pathway as our data progresses.' SANA has completed phase 1a/b trials, demonstrating safety, tolerability, and early efficacy over 15 days of treatment, she told Medscape Medical News . 'If upcoming phase 2 trials replicate these results and support a clear benefit-risk profile, we believe SANA could potentially reach the market within the next 4-5 years, subject to regulatory pathways and ongoing trial outcomes.' The study was published online in Nature Metabolism . 'Complementary Therapeutic Approach' SANA, a nitroalkene derivative of salicylate, demonstrated efficacy in preclinical models of diet-induced obesity and significantly reduced liver steatosis and insulin resistance by enhancing mitochondrial respiration and increasing creatine-dependent energy expenditure in adipose tissue. Unlike glucagon-like peptide 1 (GLP-1) receptor agonists that are associated with muscle wasting and loss of lean mass, SANA was shown in preclinical models to significantly preserve and at times increase lean muscle mass while reducing fat mass. Specifically, EchoMRI analysis in diet-induced obese mice showed that SANA-treated animals had a greater percentage of lean body mass than control animals, despite substantial fat loss. Based on the accumulated preclinical evidence indicating that the compound might be a suitable first-in-class drug for treatment of obesity and comorbidities, the researchers embarked on a double-blind, randomized, placebo-controlled phase 1a/b study. The trial included a single ascending dose (200-800 mg) cohort of 17 lean volunteers and a multiple ascending dose (200-400 mg) cohort of 24 individuals with obesity. The primary endpoint was safety and tolerability. Secondary and exploratory endpoints included pharmacokinetics, tolerability, body weight, and metabolic markers. SANA was shown to be safe and well tolerated at all dose levels, with no serious adverse events reported. In the Phase 1b portion, patients receiving the drug experienced a significant reduction in body weight compared to placebo, along with improvements in fasting glucose and insulin resistance as measured by HOMA-IR. The metabolic improvements were observed after 2 weeks of treatment and occurred without any significant changes in diet or activity levels. 'SANA introduces a novel and potentially complementary therapeutic approach to obesity and metabolic disease — one that doesn't rely on appetite suppression but instead taps into a previously underutilized biological mechanism, namely, creatine-driven thermogenesis,' Garat said. 'It may also offer an alternative for patients who cannot tolerate GLP-1 therapies or who experience undesirable side effects. Additionally, its oral or subcutaneous dosing flexibility could support patient adherence in real-world settings.' That said, she added, 'As with any first-in-human compound, long-term safety, especially with chronic use, will need to be carefully monitored.' The study had limitations. Although the human results support the notion that SANA may be effective in humans, the trial was designed to test safety and tolerability. 'The efficacy of SANA in humans needs to be further studied in a phase 2 clinical trial, with longer treatment, increased sample number, and extended measurements to validate its efficacy and mechanism of action,' the authors wrote. 'As such, the efficacy results presented here, although promising, are still preliminary and subject to further validation.' The authors had various forms of funding, as detailed in the paper. Multiple authors declared holding shares in Eolo USA and/or serving as advisors to the company.
Medscape
an hour ago
- Medscape
Novel Herbal Emollients Plus Benefit Patients With AD
TOPLINE: A novel herbal emollient plus combination containing ginger extract and cannabidiol was effective and provided sustained relief of itch, progressive improvement of objective symptoms, and stabilisation of the skin barrier in patients with atopic dermatitis (AD) over a period of 12 weeks. METHODOLOGY: Researchers analysed 94 adults and children with AD (adults ≥ 18 years; children < 18 years) in a 12-week prospective interventional monocentric trial. Participants applied BNO 3732 body lotion twice daily and BNO 3731 intensive care product as needed. Both products contained ginger extract and cannabidiol as active cosmetic ingredients. Researchers evaluated outcomes using the peak pruritus numerical rating scale, Recap of atopic eczema (RECAP), Dermatology Quality of Life Index (DLQI), children's DLQI (CDLQI), and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD). In adult subgroups, researchers assessed the epidermal barrier integrity via intercellular lipid levels, lamellar organisation, and corneocyte maturity. TAKEAWAY: A significant improvement was observed in mean RECAP sum scores (P < .001), with a 54% reduction seen in the first 4 weeks, and peak pruritus significantly decreased by 53% after 4 weeks (P < .001); the outcomes were sustained over 12 weeks. Mean vIGA-AD scores decreased by 63% over 12 weeks, with 88% of participants classified as responders and 59% achieved clearance by week 12. The skin-related quality of life for adults and children (4-15 years) significantly increased in the first 4 weeks according to the DLQI and CDLQI, respectively, followed by a progressive improvement over the remaining 8 weeks. An instrumental analysis revealed significant increases in ceramide EOS, ceramide NP, free fatty acids, and cholesterol contents after 12 weeks of product application (P ≤ .05). The mean length of lipid lamellae significantly increased from 61.08 to 196.23 nm/1000 nm2 (P < .001), reaching levels comparable with those of the healthy skin. The ratio of mature to immature corneocytes was significantly increased after 12 weeks (P < .001), indicating enhanced barrier integrity. IN PRACTICE: "Oil-in-water emulsions BNO 3732 and BNO 3731 containing the ACIs [active cosmetic ingredients] ginger extract and cannabidiol with anti-inflammatory and antioxidative in vitroactivities are efficacious beyond mere moisturizing and occlusive properties by providing sustained relief of itch, long-lasting improvement of objective AD symptoms, and stabilization of the epidermal permeability barrier," the authors of the study wrote. SOURCE: This study was led by Lars Herrmann, Bionorica SE, Neumarkt, Germany. It was published online on June 18, 2025, in Acta Dermato-Venereologica. LIMITATIONS: This study had several limitations, including the absence of a dedicated control group. Additionally, the subpanel for instrumental skin barrier analysis was reduced compared to the complete study population. The researchers also noted that no instructions were available regarding the amount of products to be used, preventing the correlation analysis between the magnitude of effects and product usage amounts. DISCLOSURES: This study was funded by Bionorica SE in Neumarkt in der Oberpfalz, Germany. Eight authors reported being employees of Bionorica SE. One author is named as an inventor on a patent application for compositions containing cannabidiol and an extract from ginger. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
